Drug

MEK Inhibitor CI-1040

CI-DRUG-00000357Explore in graph →NCIt C2670 CIViC

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	2	—	—	2002-01
Malignant Breast Neoplasm	Phase2	Phase 2	1	—	—	2002-02
Malignant Lung Neoplasm	Phase2	Phase 2	2	—	—	2002-01
Malignant Pancreatic Neoplasm	Phase2	Phase 2	1	—	—	2002-02

Computedclinicaltrials

Curated evidence

Clinical evidence (8)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–8 of 8 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PTEN V317FS1
Akt Inhibitor MK2206 +

Clinical trials

Trials with this intervention (2)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–2 of 2 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00033384	CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer	completed	Phase 2	—	University of Alabama at BirminghamOTHER	1	Apr 12, 2013	clinicaltrials
NCT00034827	A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer	completed

STK11 Loss5
MEK Inhibitor CI-1040	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	rejected	EID2319 STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype. PMID 15021901 · Carretero et al., 2004 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	rejected	EID2320 STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype. PMID 21102257 · Marcus et al., 2010 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	rejected	EID2321 STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype. PMID 12097271 · Sanchez-Cespedes et al., 2002 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	—	rejected	EID2322 STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype. PMID 18948947 · Ding et al., 2008 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	—	submitted	EID2318 NSCLC cell lines that contain inactivating STK11 mutations and activating KRAS mutations have shown a reduced proliferation rate in response to the MEK inhibitor CI-1040 (P<0.001) compared to NSCLC ce… (full text at CIViC) PMID 19165201 · Mahoney et al., 2009 · Open in CIViC	civic

STK11 Loss5

MEK Inhibitor CI-1040

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

—

rejected

EID2319

STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype.

PMID 15021901 · Carretero et al., 2004 · Open in CIViC

civic

〃

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

—

rejected

EID2320

STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype.

PMID 21102257 · Marcus et al., 2010 · Open in CIViC

civic

〃

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

—

rejected

EID2321

STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype.

PMID 12097271 · Sanchez-Cespedes et al., 2002 · Open in CIViC

civic

〃

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

—

rejected

EID2322

STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype.

PMID 18948947 · Ding et al., 2008 · Open in CIViC

civic

〃

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

—

submitted

EID2318

NSCLC cell lines that contain inactivating STK11 mutations and activating KRAS mutations have shown a reduced proliferation rate in response to the MEK inhibitor CI-1040 (P<0.001) compared to NSCLC ce… (full text at CIViC)

PMID 19165201 · Mahoney et al., 2009 · Open in CIViC

civic

BRAF V600E2
MEK Inhibitor CI-1040	Malignant Thyroid Gland Neoplasm	Predictive	B	Supports Sensitivity Response	—	rejected	EID2138 In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC) PMID 21882184 · Kim et al., 2012 · Open in CIViC	civic
〃	Malignant Thyroid Gland Neoplasm	Predictive	D	Supports Sensitivity Response	—	submitted	EID2136 Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to the MAPK inhibitor CI-1040 than those with wildtype BRAF (IC50: 0.031-1.251 uM vs. 44.376-278.286 uM). In a mouse xenograft m… (full text at CIViC) PMID 17911174 · Liu et al., 2007 · Open in CIViC	civic

BRAF V600E2

MEK Inhibitor CI-1040

Malignant Thyroid Gland Neoplasm

Predictive

Supports Sensitivity Response

—

rejected

EID2138

In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC)

PMID 21882184 · Kim et al., 2012 · Open in CIViC

civic

〃

Malignant Thyroid Gland Neoplasm

Predictive

Supports Sensitivity Response

—

submitted

EID2136

Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to the MAPK inhibitor CI-1040 than those with wildtype BRAF (IC50: 0.031-1.251 uM vs. 44.376-278.286 uM). In a mouse xenograft m… (full text at CIViC)

PMID 17911174 · Liu et al., 2007 · Open in CIViC

civic